Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

DuPont Rejects Activist Investor

by Alexander H. Tullo
February 9, 2015 | A version of this story appeared in Volume 93, Issue 6

DuPont has named two new board directors in an attempt to trump Trian Partners, the activist hedge fund led by Nelson Peltz that is trying to place four of its own directors on DuPont’s board. DuPont has appointed James L. Gallogly and Edward D. Breen to replace two directors who are resigning to serve on the board of DuPont’s chemical spin-off, Chemours. Gallogly retired last year as CEO of LyondellBasell Industries. Breen is chairman of Tyco International. Peltz’s four nominees include himself. In a letter to Peltz, DuPont CEO Ellen J. Kullman explained that DuPont rejected three of his nominees but offered to support one if Peltz would support DuPont’s two new directors. “We are disappointed that you refused to consider any path forward that did not involve putting you personally on the board,” she noted.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.